Search results
CAR-T therapy achieves lupus remission breakthrough
BioPharma-Reporter· 3 days agoThis is the first trial to date to show safe elimination of all autoantibodies in patients with systemic lupus erythematosus (SLE) and lupus< ...
Mouth Ulcers: What Are They And How Do You Get Them
Health via Yahoo News· 7 days agoThe exact cause of mouth ulcers is unknown. An injury inside your mouth from braces or a virus can lead to a mouth ulcer. Health conditions like...
CIDP study explores dual-target CAR-T cell therapy for the treatment of relapsed/refractory...
Medical Xpress· 1 day agoThis study was led by Professor Junnian Zheng and Ming Shi from the Cancer Institute of Xuzhou Medical University, together with the team of Professor Guiyun Cui and Wei Zhang from the Affiliated ...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 5 days agoFate Therapeutics is also advancing its...Additionally, the company has plans to submit an...
Hyperkeratosis in Dogs: Symptoms, Causes, & Treatments
Dog Time via AOL· 3 days agoHyperkeratosis in dogs is a condition characterized by the thickening of the skin’s outer layer due...
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase...
FOX 23 News Albany· 7 days agoThe study results were featured in a late-breaking presentation (LBA0010) and are among 30 abstracts...
Top projects awarded at PCOM South Georgia Research Day
The Albany Herald, Ga. via Yahoo News· 7 days agoKeynote speaker Dr. Jennifer McQuiston, deputy director in the Division of High Consequence Pathogens and Pathology in the Centers for Disease Control and Prevention, began ...
Corbus Pharmaceuticals Board Member To Sell Shares In Planned Trading - Corbus Pharmaceuticals...
Benzinga· 4 days agoIn a recent move signaling strategic financial planning, Corbus Pharmaceuticals Holdings, Inc. CRBP...
Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Oppenheimer
ETF DAILY NEWS· 7 days agoOppenheimer restated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $50.00 price ...
Citi maintains Buy rating on Cabaletta Bio post-EULAR data By Investing.com
Investing.com· 5 days agoOn Monday, Citi reaffirmed its positive stance on Cabaletta Bio Inc . The endorsement follows the...